George D Demetri

George D Demetri

UNVERIFIED PROFILE

Are you George D Demetri?   Register this Author

Register author
George D Demetri

George D Demetri

Publications by authors named "George D Demetri"

Are you George D Demetri?   Register this Author

100Publications

3159Reads

16Profile Views

The effect of gastrectomy on regorafenib exposure and progression-free survival in patients with advanced gastrointestinal stromal tumours.

Br J Clin Pharmacol 2019 Oct 19;85(10):2399-2404. Epub 2019 Aug 19.

Department of pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bcp.14061DOI Listing
October 2019

Cyclin D1 is a mediator of gastrointestinal stromal tumor KIT-independence.

Oncogene 2019 Sep 1;38(39):6615-6629. Epub 2019 Aug 1.

Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41388-019-0894-3DOI Listing
September 2019

Evolution of the International Sarcoma Community: A Personal Perspective.

Authors:
George D Demetri

Oncology 2018 14;95 Suppl 1:1-4. Epub 2018 Dec 14.

Dana-Farber Cancer Institute, Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000494859DOI Listing
January 2019

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

N Engl J Med 2018 02;378(8):731-739

From Memorial Sloan Kettering Cancer Center (A. Drilon, J.F.H., R.B., M.L., D.M.H.) and Weill Cornell Medical College (A. Drilon, D.M.H.), New York; University of Texas Southwestern Medical Center-Children's Health, Dallas (T.W.L.); Stanford Cancer Center, Stanford University, Palo Alto (S.K.), Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California (L.M.), and UCLA David Geffen School of Medicine (N.F.), Los Angeles, and Loxo Oncology, South San Francisco (B.B.T., K.E., S.C., N.C.K., M.C.C.) - all in California; Dana-Farber-Boston Children's Cancer and Blood Disorders Center (S.G.D.), Dana-Farber Cancer Institute (G.D.D., M.N.), Ludwig Center at Harvard (G.D.D.), and Massachusetts General Hospital (A.F.F.) - all in Boston; the Finsen Center, Rigshospitalet, Copenhagen (U.N.L.); University of Colorado, Aurora (R.C.D.); St. Jude Children's Research Hospital, Memphis (A.S.P.), and Vanderbilt University, Nashville (J.B.) - both in Tennessee; Cincinnati Children's Hospital Medical Center, Cincinnati (B.T.); University Hospitals of Cleveland Medical Center (A. Dowlati) and Taussig Cancer Institute, Cleveland Clinic (D.P.S.S.), Cleveland; University of Pennsylvania Perelman School of Medicine, Department of Otorhinolaryngology and Head and Neck Surgery, and the Abramson Cancer Center (M.S.B.), and Fox Chase Cancer Center (W.S.E.-D.), Philadelphia; University of Washington-Seattle Cancer Care Alliance (C.B.), Seattle Children's Hospital (E.R.R.), and Seattle Children's Hospital, University of Washington, Fred Hutchinson Cancer Research Center (D.S. Hawkins), Seattle; University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B., D.S. Hong); Inova Schar Cancer Institute, Falls Church, VA (J.D.); START Madrid, Centro Integral Oncológico Clara Campal, Madrid (V.B.); Nemours Children's Hospital, Orlando (R.N.), and Memorial Cancer Institute-Florida International University, Miami (L.E.R.) - both in Florida; Oregon Health and Science University, Portland (M.T.); and WVU Cancer Institute, West Virginia University, Morgantown (P.C.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1714448DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857389PMC
February 2018

Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.

J Clin Oncol 2017 Oct 30;35(30):3433-3439. Epub 2017 Aug 30.

George D. Demetri, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Patrick Schöffski, University Hospitals Leuven, Leuven, Belgium; Giovanni Grignani, Fondazione del Piemonte per l'Oncologia Istituto di Ricovero e Cura a Carattere Scientifico, Candiolo, Italy; Jean-Yves Blay, Université Claude Bernard and Centre Léon Bérard, Lyon, France; Robert G. Maki, Monter Cancer Center, Lake Success; and Cold Spring Harbor Laboratory, New Hyde Park, NY; Brian A. Van Tine, Barnes and Jewish Hospital, Washington University in St. Louis, St. Louis, MO; Thierry Alcindor, McGill University Health Centre, Montreal, Quebec, Canada; Robin L. Jones, The Royal Marsden Hospital, Institute of Cancer Research, London, United Kingdom; David R. D'Adamo and Matthew Guo, Eisai, Woodcliff Lake, NJ; and Sant Chawla, Sarcoma Oncology Center, Santa Monica, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.6605DOI Listing
October 2017

Defining the Impact of Adjuvant Therapy in Molecularly Defined Subsets of Gastrointestinal Stromal Tumor : From Lumping to Splitting.

JAMA Oncol 2017 05;3(5):597-599

Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.5740DOI Listing
May 2017

Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.

Immunity 2017 02;46(2):197-204

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.immuni.2017.02.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408320PMC
February 2017

Advances and controversies in the management of soft tissue sarcomas.

Future Oncol 2017 Jan;13(1s):3-11

Fondazione IRCCS Istituto Nazionale Tumori & University of Milan, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2016-0498DOI Listing
January 2017

A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor.

Expert Opin Drug Saf 2016 27;15(4):571-8. Epub 2016 Feb 27.

b Center for Sarcoma and Bone Oncology and Ludwig Center at Harvard , Dana-Farber Cancer Institute and Harvard Medical School , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14740338.2016.1152258DOI Listing
December 2016

Reply to S. Rastogi et al.

Authors:
George D Demetri

J Clin Oncol 2016 10;34(29):3583

Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.3029DOI Listing
October 2016

A new model: physician-patient collaboration in online communities and the clinical practice of oncology.

Am Soc Clin Oncol Educ Book 2012 :443-8

From the Department of Thoracic Oncology, Swedish Cancer Institute, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2012.32.443DOI Listing
April 2016

How to decide whether to offer and use "nonstandard" therapies in patients with advanced sarcomas and gastrointestinal stromal tumors: global variations in clinical practice, assessment, and access to therapies in diseases with limited incidence and data.

Am Soc Clin Oncol Educ Book 2012 :645-50

From the Erasmus MC Daniel Den Hoed Cancer Center, Rotterdam, Netherlands; CR UK Centre for Cancer Therapeutics, Sutton, United Kingdom; Ludwig Center and Sarcoma Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2012.32.645DOI Listing
April 2016

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

J Clin Oncol 2016 Mar 14;34(8):786-93. Epub 2015 Sep 14.

George D. Demetri, Dana-Farber Cancer Institute and Ludwig Center at Harvard, Boston, MA; Margaret von Mehren, Fox Chase Cancer Center; Arthur Staddon, University of Pennsylvania, Philadelphia; Hussein Tawbi, University of Pittsburgh Cancer Institute, Pittsburgh, PA; Robin L. Jones, Seattle Cancer Care Alliance, Seattle, WA; Martee L. Hensley, Memorial Sloan Kettering Cancer Center; Robert G. Maki, Mount Sinai Medical Center, New York, NY; Scott M. Schuetze, University of Michigan, Ann Arbor, MI; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa City, IA; Anthony Elias, University of Colorado Cancer Center, Aurora, CO; Kristen Ganjoo, Stanford Hospital and Clinics, Stanford, CA; Brian A. Van Tine, Washington University in St Louis, St Louis, MO; Alexander Spira, Virginia Cancer Specialists, Fairfax, VA; Andrew Dean, St John of God Hospital-Bendat Cancer Centre, Subiaco, Western Australia, Australia; Nushmia Z. Khokhar, Youn Choi Park, Roland E. Knoblauch, and Trilok V. Parekh, Janssen Research & Development, Raritan, NJ; and Shreyaskumar R. Patel, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.62.4734
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.62.4734DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070559PMC
March 2016

Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma.

Oncotarget 2016 Mar;7(13):16581-92

Ludwig Center at Dana-Farber/Harvard and Center for Sarcoma and Bone Oncology, Department of Medical Oncology, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.7667DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941336PMC
March 2016

Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT).

Eur J Cancer 2016 Jan 14;52:201-8. Epub 2015 Dec 14.

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2015.10.071DOI Listing
January 2016

Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.

Circulation 2015 Dec;132(23):2248-58

From Department of Medicine, Brigham and Women's Hospital, Boston, MA (A.M.B., G.D.D.); Vanderbilt-Ingram Cancer Center (C.L.A., J.M.), Cardiovascular Division (T.F., J.J.M.), and Cardio-Oncology Program (C.L.A., T.F., J.J.M.), Vanderbilt University School of Medicine, Nashville, TN; Department of Medicine, Washington University Medical Center, St. Louis, MO (B.D.H., J.M.); Dana-Farber Cancer Institute and Ludwig Center at Harvard, Harvard Medical School, Boston, MA (G.D.D.); and Knight Cancer Institute, Oregon Health & Science University and Howard Hughes Medical Institute, Portland, OR (B.J.D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.115.010484DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863699PMC
December 2015

Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines.

Clin Cancer Res 2015 Jul 24;21(14):3178-86. Epub 2015 Mar 24.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Cancer Vaccine Center, Center for Immuno-oncology, and Melanoma Disease Center, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2932DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506240PMC
July 2015

Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion.

Oncologist 2015 Jul 12;20(7):823-30. Epub 2015 Jun 12.

Tisch Cancer Institute, Mount Sinai Medical Center, New York, New York, USA; Department of Medical Oncology, Centre Léon Bérard, Lyon, France; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA; Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Servicio de Oncología Médica, Fundación Instituto Valenciano de Oncología, Valencia, Spain; National Cancer Center Hospital East, Department of Surgery, Kashiwa, Japan; HELIOS Klinikum Berlin-Buch, Interdisciplinary Oncology, Berlin, Germany; General Medical Oncology, Leuven Cancer Institute, University Hospital Gasthuisberg, Catholic University Leuven, Leuven, Belgium; University of Miami Sylvester Cancer Center, Sarcoma Medical Oncology Program, Miami, Florida, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0471DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492234PMC
July 2015

Whole Lung Irradiation in Adults with Metastatic Ewing Sarcoma: Practice Patterns and Implications for Treatment.

Sarcoma 2015 25;2015:591698. Epub 2015 Jun 25.

Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA ; Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA ; Department of Radiation Oncology, Brigham and Women's Hospital, Boston, MA 02115, USA ; Department of Radiation Oncology, Boston's Children's Hospital, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2015/591698DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496475PMC
July 2015

c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas.

J Pathol 2014 Oct 1;234(2):190-202. Epub 2014 Aug 1.

Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA; Ludwig Center at Dana-Farber/Harvard Cancer Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.4379DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472460PMC
October 2014

Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma.

Cancer 2014 Oct 12;120(20):3154-8. Epub 2014 Jun 12.

Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28844DOI Listing
October 2014

Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo.

Mol Cancer Ther 2014 Sep 15;13(9):2184-93. Epub 2014 Jul 15.

Ludwig Center at Dana-Farber/Harvard, Harvard Medical School, Boston, Massachusetts. Department of Medical Oncology, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-14-0387DOI Listing
September 2014

Effect of gastrointestinal resection on sunitinib exposure in patients with GIST.

BMC Cancer 2014 Aug 8;14:575. Epub 2014 Aug 8.

Department of Clinical Pharmacy, Radboud University Medical Center, Route 864, Postbus 9101, 6500 HB Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1186%2F1471-2407-14-
Web Search
http://www.biomedcentral.com/1471-2407/14/575
Publisher Site
http://dx.doi.org/10.1186/1471-2407-14-575DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133599PMC
August 2014

Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care.

Oncologist 2014 Jun 12;19(6):669-80. Epub 2014 May 12.

Mayo Clinic, Rochester, Minnesota, USA; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA; University Hospital Gasthuisberg/Leuven, Leuven, Belgium; Léon Bérard Centre and Claude Bernard University, Lyon, France; IRCCS San Martino, Genoa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2013-0059DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041675PMC
June 2014

Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.

J Clin Oncol 2014 May 17;32(15):1563-70. Epub 2014 Mar 17.

Christopher L. Corless, Violetta Kolesnikova, Charles D. Blanke, Michael C. Heinrich, Oregon Health and Science University, Portland, OR; Karla V. Ballman, Mayo Clinic, Rochester, MN; Cristina R. Antonescu and Ronald P. DeMatteo, Memorial Sloan-Kettering Cancer Center; Robert G. Maki, Mt Sinai School of Medicine, New York, NY; Peter W.T. Pisters and Shreyaskumar Patel, University of Texas MD Anderson Cancer Center, Houston, TX; Martin E. Blackstein, Mount Sinai Hospital, Toronto, Ontario, Canada; George D. Demetri, Dana-Farber Cancer Institute, Boston, MA; Margaret von Mehren, Fox Chase Cancer Institute, Philadelphia, PA; Martin D. McCarter, University of Colorado School of Medicine, Aurora, CO; and Kouros Owzar, Duke University School of Medicine, Durham, NC.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2013.51.2046
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.51.2046DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4026579PMC
May 2014

International expert opinion on patient-tailored management of soft tissue sarcomas.

Eur J Cancer 2014 Mar 29;50(4):679-89. Epub 2013 Nov 29.

Mount Sinai Medical Center, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2013.11.011DOI Listing
March 2014

Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib.

Eur J Cancer 2014 Mar 2;50(5):981-6. Epub 2014 Jan 2.

Department of Imaging, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, United States; Department of Radiology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02215, United States; Ludwig Center and Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2013.11.037DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4242716PMC
March 2014

Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors.

F1000Res 2013 9;2:152. Epub 2013 Jul 9.

Department of Biostatistics, Harvard School of Public Health, Boston MA, 02215, USA ; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12688/f1000research.2-152.v1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892920PMC
February 2014

A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.

Clin Cancer Res 2013 Nov 17;19(21):6020-9. Epub 2013 Sep 17.

Authors' Affiliations: Dana-Farber Cancer Institute and Harvard Medical School; Ludwig Center at Dana-Farber/Harvard Cancer Center, Boston, Massachusetts; University of Michigan, Ann Arbor, Michigan; UCLA Division of Hematology-Oncology, Santa Monica, California; Pinnacle Oncology, Scottsdale, Arizona; and Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0953DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4330562PMC
November 2013

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.

J Clin Oncol 2013 Sep 17;31(26):3182-90. Epub 2013 Jun 17.

F. Stephen Hodi, Anita Giobbie-Hurder, Philip Friedlander, Jason J. Luke, Katherine A. Zukotynski, Jeffrey T. Yap, Annick D. Van den Abbeele, and George D. Demetri, Dana-Farber Cancer Institute; Jonathan A. Fletcher, Meijun Zhu, and Adrian Marino-Enriquez, Brigham and Women's Hospital; Donald Lawrence, Keith T. Flaherty, and David E. Fisher, Massachusetts General Hospital, Boston, MA; Christopher L. Corless, Michael C. Heinrich, and Carol Beadling, Portland Veterans Administration Medical Center and Oregon Health & Science University, Portland, OR; Philip Friedlander, Mount Sinai Medical Center, New York, NY; Rene Gonzalez, University of Colorado Cancer Center, Aurora, CO; Jeffrey S. Weber, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Thomas F. Gajewski, University of Chicago, Chicago, IL; Steven J. O'Day, Beverly Hills Cancer Center, Beverly Hills, CA; Kevin B. Kim, The University of Texas MD Anderson Cancer Center, Houston, TX; Frances A. Collichio, The University of North Carolina at Chapel Hill, Chapel Hill, NC; and Marc S. Ernstoff, Geisel School of Medicine and Norris Cotton Cancer Center, Hanover, NH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.47.7836DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878082PMC
September 2013

Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.

Ann Surg 2013 Sep;258(3):422-9

*Memorial Sloan-Kettering Cancer Center, New York, NY †Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN ‡Oregon Health Sciences University, Portland, OR §Fox Chase Cancer Center, Philadelphia, PA ¶University of Colorado School of Medicine, Aurora, CO ‖Stanford University School of Medicine, Stanford CA **Mt Sinai School of Medicine, New York, NY ††University of Texas MD Anderson Cancer Center, Houston, TX ‡‡Dana Farber Cancer Institute, Boston, MA; and §§Alliance Statistics and Data Center, Duke University, Durham, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/SLA.0b013e3182a15eb7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041735PMC
September 2013

Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy.

Clin Cancer Res 2013 Jul 28;19(14):3796-807. Epub 2013 May 28.

Ludwig Center at Dana-Farber/Harvard and Center for Sarcoma and Bone Oncology, Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-3647DOI Listing
July 2013

Modifying phase I methodology to facilitate enrolment of molecularly selected patients.

Eur J Cancer 2013 May 16;49(7):1515-20. Epub 2013 Jan 16.

Service d'Innovation Thérapeutiques et Essais Précoces, Institut Gustave Roussy, Université Paris XI, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2012.12.012DOI Listing
May 2013

Imaging features of bone metastases in patients with gastrointestinal stromal tumors.

Diagn Interv Radiol 2012 Jul-Aug;18(4):391-6. Epub 2012 Mar 9.

Department of Radiology, Harvard Medical School, Dana Farber Cancer Institute, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4261/1305-3825.DIR.5179-11.1DOI Listing
December 2012

Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors.

Authors:
George D Demetri

Semin Oncol 2011 Apr;38 Suppl 1:S10-9

Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00937754110002
Publisher Site
http://dx.doi.org/10.1053/j.seminoncol.2011.01.018DOI Listing
April 2011

mTOR inhibitors in sarcoma.

Authors:
George D Demetri

Clin Adv Hematol Oncol 2011 Feb;9(2):145-7

Ludwig Center at Dana-Farber/Harvard Cancer Center and Sarcoma Center, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
February 2011

Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification.

Int J Cancer 2010 Dec;127(11):2718-22

Department of Pediatric Hematology-Oncology, Dana Farber Cancer Institute and Children's Hospital, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.25247DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2947557PMC
December 2010

Disease state awareness in sarcoma.

Authors:
George D Demetri

Clin Adv Hematol Oncol 2010 Aug;8(8):543-5

Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
August 2010

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

Cancer Chemother Pharmacol 2010 Jul 5;66(2):357-71. Epub 2009 Dec 5.

Pfizer Inc., Global Research and Development, 10578 Science Center Drive, CB1, San Diego, CA 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-009-1170-yDOI Listing
July 2010

Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate.

Ann Surg Oncol 2010 Feb 7;17(2):407-15. Epub 2009 Nov 7.

Department of Surgery, Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-009-0784-yDOI Listing
February 2010

Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage.

J Clin Oncol 2009 Nov 5;27(33):e198-200. Epub 2009 Oct 5.

Division of Plastic Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.21.6473DOI Listing
November 2009

Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.

Clin Cancer Res 2009 Oct 29;15(19):6232-40. Epub 2009 Sep 29.

Ludwig Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-0224DOI Listing
October 2009